Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avapritinib in Pediatric Relapsed/Refractory CBF-AML with KIT Mutation
NCT06316960Phase 2Recruiting
- Sponsor
- Children's Hospital of Soochow University
- Start
- Mar 2024
- Primary completion
- Mar 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avapritinib in acute myeloid leukemia (AML), sponsored by Children's Hospital of Soochow University. Primary endpoint: Composite remission rate. Started Mar 2024; status: recruiting.
02
Drugs
avapritinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06316960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06316960.